logo-loader

HemoGenyx CEO says progress 'definitely surpassing expectations'

Published: 10:00 11 May 2018 BST

Dr Vladislav Sandler, chief executive of HemoGenyx Pharmaceuticals PLC (LON:HEMO), tells Proactive Investors they've entered into a collaboration agreement with Rockefeller University to use their new type of humanised mice for autoimmune disease modelling in an effort to develop new treatment for autoimmune diseases, specifically Lupus.

The first stage of development work will create mice that emulate the human symptoms of Lupus, while the second stage will then focus on the development of multi-specific antibodies and cell therapies to treat the disease in these mice.

Hemogenyx Pharmaceuticals discusses successful £3.5M capital raise as it...

Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) Dr Vladislav Sandler joins Proactive's Stephen Gunnion after the pre-clinical stage biopharmaceutical group raised £3.5 million, which will be utilized to progress its lead product candidate, Chimeric Antigen Receptor T-cells (HEMO-CAR-T), into...

2 weeks, 2 days ago